Kehinde Idowu

Kehinde Idowu

Auto-generated profile, based on publicly available information

Kehinde Idowu

Texas Southern Univ

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
JAJamiy Olaseni Aribisala
Jamiy Olaseni Aribisala
SNSonto Nkosi
Sonto Nkosi
KIKehinde Idowu
Kehinde Idowu
INIsmaila Olanrewaju Nurain
Ismaila Olanrewaju Nurain
GMGaositwe Melvin Makolomakwa
Gaositwe Melvin Makolomakwa
SSSaheed Sabiu
Saheed Sabiu
The involvement of cellular oxidative stress in antibacterial therapy has remained a topical issue over the years. In this study, the contribution of oxidative stress to astaxanthin‐mediated bacterial lethality was evaluated in silico and in vitro. For the in vitro analysis, the minimum inhibitory concentration (MIC) of astaxanthin was lower than that of novobiocin against Staphylococcus aureus but generally higher than those of the reference antibiotics against other test organisms. The level of superoxide anion of the tested organisms increased significantly following treatment with astaxanthin when compared with DMSO‐treated cells. This increase compared favorably with those observed with the reference antibiotics and was consistent with a decrease in the concentration of glutathione (GSH) and corresponding significant increase in ADP/ATP ratio. These observations are suggestive of probable involvement of oxidative stress in antibacterial capability of astaxanthin and in agreement with the results of the in silico evaluations, where the free energy scores of astaxanthins’ complexes with topoisomerase IV ParC and ParE were higher than those of the reference antibiotics. These observations were consistent with the structural stability and compactness of the complexes as astaxanthin was observed to be more stable against topoisomerase IV ParC and ParE than DNA Gyrase A and B. Put together, findings from this study underscored the nature and mechanism of antibacterial action of astaxanthin that could suggest practical approaches in enhancing our current knowledge of antibacterial arsenal and aid in the novel development of alternative natural topo2A inhibitor.

10 May 2021 in Journal of Complementary and Integrative Medicine
Verified
Journal Article
Closed access
OMOlorunfemi R. Molehin
Olorunfemi R. Molehin
KIKehinde A. Idowu
Kehinde A. Idowu
AOAyonposi B. Olaoye
Ayonposi B. Olaoye
AFAderonke E. Fakayode
Aderonke E. Fakayode
OAOluwatumininu O. Adesua
Oluwatumininu O. Adesua
Objectives Doxorubicin (DOX) is a commonly used chemotherapeutic drug. However, its non-target organ toxicities pose a serious problem. This study is to assess the protective role of Clerodendrum volubile leaf extract (CVE) against DOX-induced toxicities in rats. In addition, the inhibitory activities of three phytochemical compounds (Rutin, Gallic acid and Rosmarinic acid ) from CVE against Carbonyl reductase 1 (CBR1) were examined. Methods Rats were randomly divided into 5 groups: (a) Control group rats were given 0.9% NaCl as vehicle, (b) DOX group: A single dose of DOX (25 mg/kg; i.p.) was administered and rats were sacrificed 4 days after DOX injection, while groups (c–e) CVE-treated DOX rat groups were given 125, 250 and 500 mg/kg body weight of extracts orally for 12 consecutive days; 8 days before, and 4 days after the DOX administration. Computational techniques were used to determine the inhibitory activities of the compounds against CBR1. Results DOX intoxication caused a significant increase (p<0.05) in serum marker enzymes: ALT, AST, ALP, LDH, CK activities. The levels of liver and heart tissues antioxidant parameters: GPx, SOD, CAT, and GSH were significantly (p<0.05) decreased in DOX-intoxicated rats with concomitant elevation of malondialdehyde levels. Pretreatment with CVE reversed the above trends. From the structural analysis, Rutin and RSA exhibited the highest binding free energies against CBR1, and also exhibited structural stability when bound with CBR1. Conclusions Our study indicates the protective effect of CVE when used in combination with doxorubicin thus improving its chemotherapeutic application via inhibition of CBR-mediated metabolism.

26 March 2026 in JMIR Preprints
Verified
Preprint
Open access
CTCreaque Charles Tyler
Creaque Charles Tyler
Ivy Oiyee PoonIvy Oiyee Poon
Ivy Oiyee Poon
JWJawaun Willoughby
Jawaun Willoughby
MJMarcus Johnson
Marcus Johnson
FSFelcia Skelton
Felcia Skelton
KIKehinde Idowu
Kehinde Idowu
BACKGROUND African Americans (AAs) experience higher rates of hypertension (HTN) and related cardiovascular and stroke mortality compared with the general U.S. population. Interestingly, studies have shown that AAs take more antihypertensive medications but are less likely to adhere to the prescribed medication regimens compared to the general population. Additionally, participants in qualitative studies have expressed that HTN self-management, particularly lifestyle modifications, should receive more attention than increasing medications. OBJECTIVE The objectives of this study are: 1) to evaluate the synergistic effect of a pharmacist and community health worker (Pharm+CHW) intervention compared to a Pharmacist alone (Pharm control group) to improve blood pressure (BP) control in a predominantly AA cohort aged ≥ 55 years in a prospective randomized trial (n=480); 2) to identify factors correlated with clinical BP outcomes. METHODS This is a randomized clinical trial to investigate novel behavioral intervention strategies targeting HTN self-management (e.g., medication management, blood pressure monitoring) and lifestyle modifications. The study has two components: a pharmacist-led medication management component (Pharm) and a community health worker support component (CHW). In the Pharm component, pharmacists will provide virtual Medication Therapy Management (MTM) services, which include: a comprehensive medication review, recommendations for lifestyle modifications, blood pressure self-monitoring education, and medication management app education. In the CHW component, CHW will support participants’ self-initiation of behavioral change(s), address challenges to lifestyle modification, and provide health education through workshops. The study intervention will be guided by a Community Advisory Board (CAB) consisting of six members. The study will recruit a cohort of 480 predominantly AA adults 55 years or older with HTN through community-and faith-based organizations and clinics in Houston, Texas, U.S. Participants will be prospectively randomized to one of the two parallel groups: 1) Pharmacist alone (control group; n=240); or 2) Pharmacist and CHW interventions (Pharm+CHW; n=240) for 24 months. Computer-generated randomization, with 1:1 allocation stratified by age, recruitment site, and HTN stage, will be applied. The primary self-monitoring BP outcome will be measured at 0-, 6-, 12-, 18-, and 24-months to evaluate the effectiveness of the proposed interventions. The secondary outcomes will include medication adherence, hypertension knowledge, perceived competency, body mass index, and physical activity. RESULTS The study was funded by the National Institute on Minority Health and Health Disparities of the National Institutes of Health under award number 2U54MD007605 in September 2025. The CAB has convened and offered support for recruitment efforts. Recruitment is ongoing, and the intervention is expected to begin in summer 2026. CONCLUSIONS This project will fill an important knowledge gap regarding the synergistic effect of CHWs working in collaboration with pharmacists to help older adults use technologies (e.g., virtual visits, mobile medication management apps) and initiate lifestyle modifications for HTN self-management in older adult AAs. CLINICALTRIAL NCT07413159

18 May 2023 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
KIKehinde Idowu
Kehinde Idowu
COCollins Onyenaka
Collins Onyenaka
NHNgan Ha
Ngan Ha
EGEdward A. Graviss
Edward A. Graviss
OOOmonike Arike Olaleye
Omonike Arike Olaleye
ID 26564 Poster Board 94 Despite recent progress in the diagnosis of Tuberculosis (TB), the chemotherapeutic management of TB is still challenging. Mycobacterium tuberculosis (Mtb) is the etiological agent of TB, and TB is classified as the 13th leading cause of death globally. It is estimated that 558,000 people were reported to develop multi-drug resistant TB globally. Our research focuses on targeting Methionine Aminopeptidase (MetAP), an essential protein for the viability of Mtb. MetAP is a metalloprotease that catalyzes the N-terminal methionine excision (NME) during protein synthesis. This essential role of MetAPs allows this enzyme an auspicious target for the development of novel therapeutic agents for the treatment of TB. Mtb possesses 2 MetAP1 isoforms: MtMetAP1a and MtMetAP1c. In our study, we cloned, overexpressed recombinant MtMetAP1c, and investigated the in vitro inhibitory effect of OJT008 on cobalt and nickel ion activated MtMetAP1c and the mechanism of action was elucidated through an in-silico approach. The compound’s potency against replicating and multidrug-resistant (MDR) Mtb strains was also investigated. The induction of the overexpressed recombinant MtMetAP1c was optimized at 8 hours with a final concentration of 1mM Isopropyl β-D-1-thiogalactopyranoside. The average yield for MtMetAP1c was 4.65mg mg/L of Escherichia coli culture. A preliminary MtMetAP1c metal dependency screen Providedoptimum activation with nickel and cobalt ions at 100μM. The half maximal inhibitory concentration (IC50) values of OJT008 against MtMetAP1c activated with CoCl2 and NiCl2 were 11μM and 40 μM respectively. The in-silico study showed OJT008 strongly binds to both metals activated MtMetAP1c, as evidenced by strong molecular interactions and higher binding score thereby corroborating our result. This in-silico study validated the pharmacophore’s metal specificity. The potency of OJT008 against drug sensitive and MDR Mtb was < 0.063 μg/mL. Our study reports OJT008 as an inhibitor of MtMetAP1c which is potent at low micromolar concentrations against both drug-sensitive and MDR-Mtb. These results suggest OJT008 is a potential lead compound for the development of novel small molecules for the therapeutic management of TB. This project is sponsored by NIH-RCMI (U54MD007605) Grants.

26 March 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
CTCreaque Charles Tyler
Creaque Charles Tyler
Ivy Oiyee PoonIvy Oiyee Poon
Ivy Oiyee Poon
WLWenting Liu
Wenting Liu
JWJawaun Willoughby
Jawaun Willoughby
MJMarcus Johnson
Marcus Johnson
KIKehinde Idowu
Kehinde Idowu